Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGXXNASDAQ:CDXCNASDAQ:MNMDOTCMKTS:MRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21753,536 shs554,788 shsMNMDMind Medicine (MindMed)$6.45+4.9%$6.12$4.70▼$10.44$486.12M2.521.37 million shs724,349 shsMRMDMariMed$0.09-10.5%$0.10$0.07▼$0.29$36.93M3.15400,762 shs1.81 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGXXBright Green0.00%0.00%0.00%+50.00%-71.68%CDXCChromaDex0.00%0.00%0.00%+43.00%+129.97%MNMDMind Medicine (MindMed)+4.71%-1.53%+18.78%-21.63%-30.35%MRMDMariMed-10.53%-16.67%+8.83%-34.36%-67.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/ACDXCChromaDex2.9047 of 5 stars3.50.00.04.00.00.01.9MNMDMind Medicine (MindMed)2.2813 of 5 stars3.63.00.00.02.20.80.6MRMDMariMed1.0949 of 5 stars0.05.00.00.02.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGXXBright Green 0.00N/AN/AN/ACDXCChromaDex 3.00Buy$9.03∞ UpsideMNMDMind Medicine (MindMed) 3.23Buy$25.11289.32% UpsideMRMDMariMed 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MRMD, CDXC, BGXX, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/3/2025MRMDMariMedNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/17/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/10/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.003/7/2025MNMDMind Medicine (MindMed)Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$27.00 ➝ $16.003/7/2025MNMDMind Medicine (MindMed)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.003/5/2025CDXCChromaDexLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.80 ➝ $8.10(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/ACDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/AMRMDMariMed$148.60M0.22$0.02 per share5.59$0.19 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/ACDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/AMNMDMind Medicine (MindMed)-$95.73M-$1.29N/AN/AN/AN/A-47.56%-35.55%N/AMRMDMariMed-$16.03M-$0.03N/A∞N/A-10.97%-2.75%-1.06%N/ALatest MRMD, CDXC, BGXX, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/7/2025Q1 2025MRMDMariMed-$0.01-$0.01N/A-$0.01$38.33 million$37.96 million3/6/2025Q4 2024MNMDMind Medicine (MindMed)-$0.33-$0.41-$0.08-$0.41N/AN/A3/5/2025Q4 2024MRMDMariMed-$0.01-$0.01N/A-$0.02$42.00 million$39.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGXXBright GreenN/AN/AN/AN/AN/ACDXCChromaDexN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGXXBright GreenN/A0.010.01CDXCChromaDexN/A2.952.35MNMDMind Medicine (MindMed)0.099.009.00MRMDMariMed1.011.550.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGXXBright Green7.83%CDXCChromaDex15.41%MNMDMind Medicine (MindMed)27.91%MRMDMariMed0.18%Insider OwnershipCompanyInsider OwnershipBGXXBright Green62.55%CDXCChromaDex9.64%MNMDMind Medicine (MindMed)2.45%MRMDMariMed18.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGXXBright Green2191.17 million71.59 millionNo DataCDXCChromaDex12077.75 million69.02 millionOptionableMNMDMind Medicine (MindMed)4075.37 million71.68 millionOptionableMRMDMariMed260388.71 million301.65 millionNot OptionableMRMD, CDXC, BGXX, and MNMD HeadlinesRecent News About These CompaniesContrasting Entourage Health (OTC:ETRGF) and MariMed (OTCMKTS:MRMD)May 11 at 2:21 AM | americanbankingnews.comMariMed Inc.: MariMed Reports First Quarter 2025 EarningsMay 8, 2025 | finanznachrichten.deMariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2025 | zacks.comMariMed Reports First Quarter 2025 EarningsMay 7, 2025 | globenewswire.comDemand Brands (OTCMKTS:DMAN) & MariMed (OTCMKTS:MRMD) Head-To-Head SurveyMay 7, 2025 | americanbankingnews.comMariMed Announces First Quarter 2025 Earnings DateApril 8, 2025 | globenewswire.comMariMed Promotes Ryan Crandall to Chief Commercial OfficerApril 7, 2025 | globenewswire.comMariMed's Betty's Eddies Expands Top-Selling Brand With Introduction of THC & CBG-Infused Caramel ChewsApril 3, 2025 | globenewswire.comMarimed launches Nature’s Heritage Flower in IllinoisApril 1, 2025 | markets.businessinsider.comMariMed Launches Nature's Heritage™ Flower in IllinoisApril 1, 2025 | globenewswire.comMariMed Inc. (PNK:MRMD) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comMariMed Reports Record Revenue Amid Strategic GrowthMarch 6, 2025 | tipranks.comMariMed has price target chopped at VentumMarch 6, 2025 | cantechletter.comMariMed Inc. (MRMD) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comMariMed Reports Fourth Quarter and Full Year 2024 EarningsMarch 5, 2025 | globenewswire.comMariMed Completes Acquisition of First State Compassion, Strengthening Market Position in DelawareMarch 3, 2025 | globenewswire.comMariMed Announces Fourth Quarter and Full Year 2024 Earnings DateFebruary 11, 2025 | globenewswire.comMariMed Commences Wholesale Operations in MissouriDecember 23, 2024 | globenewswire.comMariMed Reports Third Quarter 2024 EarningsNovember 6, 2024 | globenewswire.comInHouse by MariMed Launches Help on the Homefront, to Support Veterans Facing Housing ChallengesOctober 31, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRMD, CDXC, BGXX, and MNMD Company DescriptionsBright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.ChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Mind Medicine (MindMed) NASDAQ:MNMD$6.45 +0.30 (+4.88%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$6.49 +0.04 (+0.62%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.MariMed OTCMKTS:MRMD$0.09 -0.01 (-10.53%) As of 05/12/2025 03:43 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
